Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT04345406

Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19

ACEIs as treatment for COVID19

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

COVID

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Tanta University

Tanta, 35111, Egypt

About this study

ACEIs as suggested treatment for COVID19

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients infected with covid 19

Exclusion criteria

  • allergy or contraindications to the drug

Treatment and study plan

ACEIs

Drug

Captopril or enalapril

Other names: Enalapril, Captopril

Conventional Treatment

Drug

alexoquine

Other names: chloroquine

Primary outcomes

  1. number of patients with virological cure

    Time frame: 6 months

    number of patients with virological cure

Interested in participating?

Not yet recruiting

Trial opening soon.

Get Notified

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Official study title

Randomized Trial of ACEIs in Treatment of COVID-19

Important dates

Study start
2020
Primary completion
2029
Study completion
2029
First posted
Apr 14, 2020
Registry last updated
Apr 14, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.